FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216154346> ?p ?o ?g. }

• W3216154346 endingPage "4754" @default.
• W3216154346 startingPage "4754" @default.
• W3216154346 abstract "Abstract CD44 expression in different plasma cell diseases Introduction Myeloma is a genetically complex disease which develops via a multistep process whereby plasma cells are driven towards malignancy through the accumulation of genetic hits over time. This multistep process permits myeloma to have four recognisable clinical stages including monoclonal gammopathy of undetermined significance (MGUS) , smouldering multiple myeloma (SMM) , multiple myeloma (MM) and plasma cell leukemia (PCL). CD44 as a complex adhesion molecule, is highly expressed in a variety of solid tumors and involved in metastasis and chemotherapy resistance . Previous studies had found that CD44 was also highly expressed in MM, and associated with advanced clinical stage, extramedullary myeloma (EM) and poor survival. However the relation of CD44 expression in different plasma cell disease remain unknown. Patients and Methods Newly diagnosed MGUS (n=12), SMM (n=11), MM (n=133) and PCL (n = 8) patients who were hospitalized in our hospital from December 2017 to December 2020 were enrolled. The diagnosis was based on the criteria of the International Myeloma Working Group. CD44 was detected by flow cytometry as follows: 2 ml of heparin anticoagulated bone marrow was collected from the patients at the time of diagnosis, 1×10 6 cells were detected, and a gate was set for identifying abnormal plasma cells characterized by CD138 and CD38. CD44 positive was defined as more than 20% of the plasma cells expressed CD44. Results From December 2017 to December 2020, a total of 164 patients diagnosed in our hospital were included in the study, including 12 MGUS patients, 11 SMM patients, 133 MM patients and 8 PCL patients. The expression proportion (7.9%±11.9%, 11.2%±15.5%, 40.2%±37.7%, 81.9%±25.6%, P &lt; 0.001) and expression intensity (the mean fluorescence intensity was 1 742.8±1 023.1, 2 915.7±923.0, 6 692.6±11 275.5, 25 359.6±22 604.5, P=0.001) of CD44 on the monoclonal plasma cells of MGUS, SMM, MM and PCL patients gradually increased. In 133 MM patients, 73 cases were for CD44 positive. CD44 positive patients were more likely to show ＞3 focal bone lesion (75.3% VS 50.0%, P=0.002), and international staging system（ISS）III stage (68.5% VS 51.7%, P=0.048) compared those with CD44 negative. CD44 expression rate was significantly higher in MM patients with extramedullary disease (n=26) than those without (n=107) (56.7%VS 36.2%, P=0.031) Conclusion: Our study showed that from MGUS, SMM, MM to PCL, the CD44 expression on abnormal plasma cells was gradually increased. CD44 overexpression was associated with osteolytic lesions, advanced ISS staging and extramedullary myeloma. The results indicated that CD44 was related to the invasion degree of plasma cell disease, and could be used as a marker for differential diagnosis between different plasma cell disease. Disclosures No relevant conflicts of interest to declare." @default.
• W3216154346 created "2021-12-06" @default.
• W3216154346 creator A5003552301 @default.
• W3216154346 creator A5006700521 @default.
• W3216154346 creator A5015312242 @default.
• W3216154346 creator A5026007805 @default.
• W3216154346 creator A5032457247 @default.
• W3216154346 creator A5053496696 @default.
• W3216154346 creator A5069115984 @default.
• W3216154346 creator A5071784511 @default.
• W3216154346 creator A5082138222 @default.
• W3216154346 date "2021-11-05" @default.
• W3216154346 modified "2023-10-16" @default.
• W3216154346 title "CD44 Expression in Different Plasma Cell Diseases" @default.
• W3216154346 doi "https://doi.org/10.1182/blood-2021-146780" @default.
• W3216154346 hasPublicationYear "2021" @default.
• W3216154346 type Work @default.
• W3216154346 sameAs 3216154346 @default.
• W3216154346 citedByCount "0" @default.
• W3216154346 crossrefType "journal-article" @default.
• W3216154346 hasAuthorship W3216154346A5003552301 @default.
• W3216154346 hasAuthorship W3216154346A5006700521 @default.
• W3216154346 hasAuthorship W3216154346A5015312242 @default.
• W3216154346 hasAuthorship W3216154346A5026007805 @default.
• W3216154346 hasAuthorship W3216154346A5032457247 @default.
• W3216154346 hasAuthorship W3216154346A5053496696 @default.
• W3216154346 hasAuthorship W3216154346A5069115984 @default.
• W3216154346 hasAuthorship W3216154346A5071784511 @default.
• W3216154346 hasAuthorship W3216154346A5082138222 @default.
• W3216154346 hasBestOaLocation W32161543461 @default.
• W3216154346 hasConcept C126322002 @default.
• W3216154346 hasConcept C142724271 @default.
• W3216154346 hasConcept C143998085 @default.
• W3216154346 hasConcept C1491633281 @default.
• W3216154346 hasConcept C159654299 @default.
• W3216154346 hasConcept C163864487 @default.
• W3216154346 hasConcept C203014093 @default.
• W3216154346 hasConcept C2776364478 @default.
• W3216154346 hasConcept C2776396001 @default.
• W3216154346 hasConcept C2777250017 @default.
• W3216154346 hasConcept C2779399171 @default.
• W3216154346 hasConcept C2780007613 @default.
• W3216154346 hasConcept C2780353925 @default.
• W3216154346 hasConcept C2780932548 @default.
• W3216154346 hasConcept C502942594 @default.
• W3216154346 hasConcept C542903549 @default.
• W3216154346 hasConcept C54355233 @default.
• W3216154346 hasConcept C71924100 @default.
• W3216154346 hasConcept C86803240 @default.
• W3216154346 hasConceptScore W3216154346C126322002 @default.
• W3216154346 hasConceptScore W3216154346C142724271 @default.
• W3216154346 hasConceptScore W3216154346C143998085 @default.
• W3216154346 hasConceptScore W3216154346C1491633281 @default.
• W3216154346 hasConceptScore W3216154346C159654299 @default.
• W3216154346 hasConceptScore W3216154346C163864487 @default.
• W3216154346 hasConceptScore W3216154346C203014093 @default.
• W3216154346 hasConceptScore W3216154346C2776364478 @default.
• W3216154346 hasConceptScore W3216154346C2776396001 @default.
• W3216154346 hasConceptScore W3216154346C2777250017 @default.
• W3216154346 hasConceptScore W3216154346C2779399171 @default.
• W3216154346 hasConceptScore W3216154346C2780007613 @default.
• W3216154346 hasConceptScore W3216154346C2780353925 @default.
• W3216154346 hasConceptScore W3216154346C2780932548 @default.
• W3216154346 hasConceptScore W3216154346C502942594 @default.
• W3216154346 hasConceptScore W3216154346C542903549 @default.
• W3216154346 hasConceptScore W3216154346C54355233 @default.
• W3216154346 hasConceptScore W3216154346C71924100 @default.
• W3216154346 hasConceptScore W3216154346C86803240 @default.
• W3216154346 hasIssue "Supplement 1" @default.
• W3216154346 hasLocation W32161543461 @default.
• W3216154346 hasOpenAccess W3216154346 @default.
• W3216154346 hasPrimaryLocation W32161543461 @default.
• W3216154346 hasRelatedWork W115137046 @default.
• W3216154346 hasRelatedWork W1971653835 @default.
• W3216154346 hasRelatedWork W1973965625 @default.
• W3216154346 hasRelatedWork W2005843898 @default.
• W3216154346 hasRelatedWork W2188033972 @default.
• W3216154346 hasRelatedWork W2415489728 @default.
• W3216154346 hasRelatedWork W2893011256 @default.
• W3216154346 hasRelatedWork W2962668827 @default.
• W3216154346 hasRelatedWork W3216154346 @default.
• W3216154346 hasRelatedWork W4224216547 @default.
• W3216154346 hasVolume "138" @default.
• W3216154346 isParatext "false" @default.
• W3216154346 isRetracted "false" @default.
• W3216154346 magId "3216154346" @default.
• W3216154346 workType "article" @default.